Charles W. M. Roberts, MD, PhD
Charles W. M. Roberts, MD, PhD

Charles W. M. Roberts, MD, PhD

Member, St. Jude Faculty

  • Executive Vice President
  • Director, Comprehensive Cancer Center

Departments

Education

MD – Washington University, St. Louis, Missouri
PhD – Washington University, St. Louis, Missouri
Internship – Children’s Hospital, Boston, Massachusetts
Residency – Children’s Hospital, Boston, Massachusetts
Fellowship – Dana-Farber Cancer Institute and Children’s Hospital, Boston, Massachusetts
Research Fellowship – Children’s Hospital, Boston, Massachusetts

Honors & Awards

  • 2014  Elected to American Pediatric Society
  • 2010  Elected to American Society of Clinical Investigation
  • 2007  Elected to Society for Pediatric Research
  • 2005  Stephen E. Sallan Leadership Award

Research Interests

  • Understanding the roles of SWI/SNF complex mutations and dysfunctional chromatin remodeling in cancer
  • Improving the outcome of children with pediatric cancer

Selected Publications

Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CWM, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol Jan 28, 2016. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print]

Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nature Medicine 22: 128-34, 2016.

Kim KH, Woojin K, Howard TP, Vazquez F, Tsherniak A, Wu JN, Wang W, Haswell JR, Walensky LD, Hahn WC, Orkin SH, Roberts CWM. SWI/SNF-mutant cancers depend upon catalytic and non-catalytic activity of EZH2. Nature Medicine Dec;21(12):1491-6, 2015.

Yin J, Leavenworth JW, Li Y, Luo Q, Xie H, Liu X, Huan S, Yan H, Fu Z, Zhang LY, Zhang LT, Hao J, Wu X, Deng X, Roberts CWM, Orkin SH, Cantor H, Wang X. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. PNAS Dec. 14, 2015. [Epub ahead of print]

Fahiminya S, Witkowski L, Nadaf J, Carrot-Zhang J, Goudie C, Hasselblatt M, Lee RS, Gayden T, Roberts CWM, Biegel JA, Jabado N, Majewski J, Foulkes WD. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor. Oncotarget  Dec 4, 2015. [Epub ahead of print]

Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe'er D, Polyak K, Roberts CWM, Siu L, Snyder A, Stower H, Swanton C, Verhaak RG, Zenklusen JC, Zuber J, Zucman-Rossi J. Toward understanding and exploiting tumor heterogeneity. Nature Medicine 21(8): 846-853, 2015. PMID: 26248267.

Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Tailor-Weiner A, McKenna A, DeLuca DS, Lawrence  MS, Ambrogio L, Sougnez C, Sivachenko A, Walensky LD, Wagle N, Mora J, de Torres C, Lavarino C, dos Santos Aguiar S, Yunes JA, Brandalise SR, Mercado-Celis GE, Melendez-Zajgla J, Cárdenas-Cardós R, Velasco-Hidalgo L, Roberts CWM, Garraway LA, Rodriguez-Galindo C, Gabriel SB, Lander ES, Golub TR, Orkin SH, Getz G, Janeway KA. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA Dec 23;111:E5564-73, 2014. PMID: 25512523 PMCID: PMC4280630

Pugh TJ, Yu W, Yang J, Ambrogio L, Field A, Carter SL, Cibulskis K, Giannikopoulos P, Kiezun A, Kim J, McKenna A, Nickerson E, Getz G, Hoffner S, Messinger YH, Dehner LP, Roberts CWM, Rodriguez-Galindo C, Williams GM, Rossi CT, Meyerson M, Hill DA. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two-hit DICER1 loss resulting in retention of 5p-derived miRNA hairpins. Oncogene Nov 6;33:5295-302, 2014. PMID: 24909177 PMCID: PMC4224628

Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, Hahn WC, Roberts CWM. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nature Medicine 20(3):251-4, 2014. PMID: 24562383 PMCID: PMC3954704

Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, Romero R, Ramadan N, Phadke T, Haas K, Jaskelioff M, Wilson BG, Meyer MJ, Saenz-Vash V, Zhai H, Myer VE, Porter JA, Keen N, McLaughlin ME, Mickanin C, Roberts CWM, Stegmeier F, Jagani Z. A functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proceedings of the National Academy of Sciences USA 111(8): 3128-33, 2014. PMID: 24520176 PMCID: PMC3939885

Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, Hahn WC, Roberts CWM. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Molecular and Cellular Biology 34(6):1136-44, 2014. PMID: 24421395 PMCID: PMC3958034

Helming KC, Wang X, Roberts CWM. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 26: 309-317, 2014. PMID: 25203320 PMCID: PMC4159614

Kim KH, Roberts CWM.  Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genetics 207:365-372, 2014. PMID: 24853101 PMCID: PMC4195815

Wang X, Haswell JR, Roberts CWM. SWI/SNF (BAF) complexes are frequently mutated in cancer: mechanisms and potential therapeutic insights. Clinical Cancer Research 20: 21-7, 2014. PMID: 24122795 PMCID: PMC3947303

Mora-Blanco EL, Mishina Y, Tillman EJ, Cho Y-J, Thom CS, Pomeroy SL, Shao W, Roberts CWM. Activation of b-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene Feb 13;33:933-38, 2014. PMID: 23435428

Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, Pornon A, Romanet V, Guagnano V, Brümmendorf T, Sellers WR, Hofmann F, Roberts CWM, Graus Porta D. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One 8(10):e77652, 2013. PMID: 24204904 PMCID: PMC3813701

Tolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC, Alver BH, Tillman EJ, Evans JA, Wilson BG, Park PJ, Roberts CWM. Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proceedings of the National Academy of Sciences 110: 10165-70, 2013. PMID: 23723349 PMCID: PMC3690861

Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Jing R, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass A, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G. Mutational heterogeneity in cancer and the search for new cancer genes. Nature 499:214-8, 2013. PMID: 23770567 PMCID: PMC3919509

Kuwahara Y, Mora-Blanco EL, Banine F, Rogers A, Fletcher C, Sherman L, Roberts CWM, Weissman B. Establishment and Characterization of MRT Cell Lines from Genetically Engineered Mouse Models and the Influence of Genetic Background on Their Development. International Journal of Cancer 132:2767-77, 2013. PMID: 23197309 PMCID: PMC3605221

Lu P, Roberts CWM. The SWI/SNF tumor suppressor complex: Regulation of promoter nucleosomes and beyond.  Nucleus 4:374-378, 2013. PMID: 24145903 PMCID: PMC3899127

Lee RS, Roberts CWM. Rhabdoid tumors: an initial clue to the role of chromatin remodeling in cancer. Brain Pathology 23:200-5, 2013. PMID: 23432645

Wu JN, Roberts CWM. ARID1A Mutations in Cancer:  Another Epigenetic Tumor Suppressor? Cancer Discovery 3:35-43, 2013. PMID: 23208470 PMCID: PMC3546152

Kieran MW, Roberts CWM, Chi SN, Ligon KL, Rich BE, MacConaill LE, Garraway LA, and Biegel JA.  Absence of Oncogenic Canonical Pathway Mutations in Aggressive Pediatric Rhabdoid Tumors. Pediatric Blood and Cancer 59:1155-7, 2012. PMID: 22997201 PMCID: PMC3538080

Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougne C, Lawrence MS, Auclair D, Mora J, Golub TR, Biegel JA, Getz G, Roberts CWM. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. Journal of Clinical Investigation 122:2983-2988, 2012. PMID: 22797305 PMCID: PMC3408754

McKenna ES, Tamayo P, Cho Y-J, Tillman EJ, Mora-Blanco EL, Sansam CG, Koellhoffer EC, Pomeroy SL, Roberts CWM.  Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle 11:1956-65, 2012. PMID: 22544318 PMCID: PMC3359122

Wang X, Werneck MBF, Wilson BG, Kim H-J, Kluk MJ, Thom CS, Wischhusen JW, Evans JA, Jesneck JL, Nguyen P, Sansam CG, Cantor H, Roberts CWM. T cell receptor dependent transformation of mature memory phenotype T cells in mice. Journal of Clinical Investigation 121:3834-3845, 2011. PMID: 21926465 PMCID: PMC3195451

Wilson BG, Roberts CWM. SWI/SNF nucleosome remodelers and cancer. Nature Reviews Cancer 11:481-92, 2011.

Show More

Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PTL, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky S, Murtie J, Kelleher J, Warmuth M, Sellers WR, Roberts CWM*, Dorsch M* (*Co-corresponding senior authors and contributed equally). Loss of the Tumor Suppressor Snf5 Leads to Aberrant Activation of the Hedgehog-Gli Pathway.Nature Medicine 16:1374-6, 2010. PMID: 21076395 PMCID: PMC3859448

Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, Koellhoffer EC, Pomeroy SL, Orkin SH, Roberts CWM.Epigenetic antagonism between Polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell Oct 19;18(4):316-28, 2010. PMID: 20951942 PMCID: PMC2957473

DelBove J, Kuwahara Y, Mora-Blanco EL, Godfrey V, Funkhouser WK, Fletcher CD, Van Dyke T, Roberts CW, Weissman BE. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice. Mol Carcinog Dec; 48(12):1139-48, 2009. PMID: 19676100  PMCID: PMC3527082

Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PTL, Roberts CWM. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent upon activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.  Cancer Research 69:8094-8101, 2009.PMID: 19789351 PMCID: PMC2763035

Bourgo RJ, Siddiqui H, Fox S, Solomon D, Sansam CG, Yaniv M, Muchardt C, Metzger D, Chambon P, Roberts CWM, Knudsen ES.  SWI/SNF-Deficiency Results in Aberrant Chromatin Organization, Mitotic Failure, and Diminished Proliferative Capacity. Molecular Biology of the Cell20:3192-9, 2009. PMID: 19458193 PMCID: PMC2710832

Roberts CWM, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biology & Therapy8:412-416, 2009. PMID: 19305156 PMCID: PMC2709499

McKenna ES, Roberts CWM. Epigenetics and cancer without genomic instability. Cell Cycle 28:1-4, 2009. PMID: 19098432

Last update: February 2016